Project Grant R43AI188991
Award Date
7/23/25
Completion Date
6/30/27
Dollars Obligated
$300K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
This Project Grant award of $2,248,740.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) is funding research by Michigan State University to develop new nitro-containing compounds to treat mycobacterial infections, including tuberculosis (TB) and non-tuberculous mycobacterial (NTM) infections. The key products and services to be delivered include: Optimizing a series of novel nitrofuran compounds, such as the parent...
This federal Project Grant award of $787,171 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop novel 1,2,4-triazole and pyrrolidine compounds as potential treatments for tuberculosis (TB). The primary objectives are to demonstrate preclinical proof-of-concept for these compound classes, optimize their pharmacological properties, and investigate their unique mechanism of action compared...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $415,978 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Central Florida. The grant aims to identify novel boron-based inhibitors of mycobacterial class II aminoacyl-tRNA synthetases, which are essential enzymes for protein synthesis in Mycobacterium tuberculosis (MTB). The research will use a high-throughput screening assay to test a library of boron-containing...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $689,051 to Health Research, Inc. to develop therapeutic potential of the mycobacteriophage lysin, LysB, for the treatment of life-threatening Mycobacterium abscessus (MAB) infections. The key objectives are to generate a cocktail of complementary LysB enzymes, decipher the mechanism of MAB lysis by LysB, and...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support a $170,000 research project by Prokaryotics Incorporated to develop novel antifungal therapeutics. The goal is to perform structural biology studies on the GPI ethanolamine phosphate transferase enzyme MCD4, which is a promising target for new antifungal drug candidates. The research aims to obtain...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $294,824 to the University of Massachusetts Medical School (UMass Medical) to investigate strategies for enhancing the efficacy of antibiotics against Mycobacterium tuberculosis (MTB) infections. The key objectives are to understand the mechanistic link between glutamine starvation, immune pressure vulnerability, and...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $481,250 to The Broad Institute, Inc. to develop antimicrobial compounds that recruit the immune system to target bacteria. The project will involve biochemical, biophysical, and cell biology experiments to characterize chimeric molecules that combine bacterial binders and immune system protein binders. This research aims to create...
This Project Grant award of $265,650 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to develop novel medicinal chemistry strategies to overcome multidrug-resistant tuberculosis (MDR-TB) and rifampicin-resistant TB (RR-TB). The research aims to establish the structure-activity relationship and mechanism of action of modified rifabutin analogs that demonstrate enhanced potency against...
This $811,396 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases under CFDA 93.855 Allergy and Infectious Diseases Research, is focused on understanding the mechanisms of lipid/metabolite and drug transport in Mycobacterium tuberculosis and related mycobacteria. The major objectives are to establish the molecular mechanisms and structures of three specific MMPL transporter proteins and their complexes with interacting partner proteins. Key activities include...
This Project Grant award of $176,152, provided by the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify new drug targets against drug-tolerant strains of Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis (TB). The research aims to study the role of lipid metabolism and host-pathogen interactions in conferring drug tolerance to MTB strains with deficient glycerol...